RATIONALE-306
Regimen
- Experimental
- tislelizumab + investigator-choice chemo (cisplatin or oxaliplatin + fluoropyrimidine or paclitaxel)
- Control
- placebo + investigator-choice chemo
Population
Previously untreated advanced or metastatic ESCC, regardless of PD-L1
Key finding
mOS 17.2 vs 10.6 mo (stratified HR 0.66, 95% CI 0.54-0.80, one-sided p<0.0001); first global 1L ESCC trial demonstrating >6-mo OS gain
Source: PMID 37080222
Timeline
Guideline citations
- NCCN ESOPHAGEAL (p.47)